270 related articles for article (PubMed ID: 36620919)
1. Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
Madanat YF; Xie Z; Zeidan AM
Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919
[TBL] [Abstract][Full Text] [Related]
2. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
[TBL] [Abstract][Full Text] [Related]
4. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
5. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR; Scott BL; Boyd T; Garcia-Manero G
Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
[TBL] [Abstract][Full Text] [Related]
6. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Venugopal S; Shallis RM; Zeidan AM
Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
[TBL] [Abstract][Full Text] [Related]
7. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
Pereira MP; Herrity E; Kim DDH
Ann Hematol; 2024 Apr; 103(4):1049-1067. PubMed ID: 37770618
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Abaza Y; Zeidan AM
Cells; 2022 Jul; 11(14):. PubMed ID: 35883692
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Brunner AM; Esteve J; Porkka K; Knapper S; Traer E; Scholl S; Garcia-Manero G; Vey N; Wermke M; Janssen JJWM; Narayan R; Fleming S; Loo S; Tovar N; Kontro M; Ottmann OG; Naidu P; Sun H; Han M; White R; Zhang N; Mohammed A; Sabatos-Peyton CA; Steensma DP; Rinne ML; Borate UM; Wei AH
Am J Hematol; 2024 Feb; 99(2):E32-E36. PubMed ID: 37994196
[TBL] [Abstract][Full Text] [Related]
10. Frontline treatment options for higher-risk MDS: can we move past azacitidine?
Sallman DA; Xie Z
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):65-72. PubMed ID: 38066872
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
[TBL] [Abstract][Full Text] [Related]
14. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
Madanat Y; Sekeres MA
Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Scott LJ
Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
[TBL] [Abstract][Full Text] [Related]
17. [Updated treatment strategies for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2022; 63(6):660-666. PubMed ID: 36184521
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
19. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
20. Advances in myelodysplastic syndrome.
Santini V
Curr Opin Oncol; 2021 Nov; 33(6):681-686. PubMed ID: 34474438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
